The Food and Drug Administration granted full approval to Moderna’s two-dose COVID-19 vaccine, marketed under the name Spikevax, more than a year after authorizing it for public use.
“The FDA’s approval of Spikevax is a significant step in the fight against the COVID-19 pandemic, marking the second vaccine approved to prevent COVID-19,” said acting FDA Commissioner Janet Woodcock. “The public can be assured that Spikevax meets the FDA’s high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States.”
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.